Clinical Trial: CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Clinical Investigation of Chimeric CD(Cluster of Differentiation)33 Antigen Receptor-modified NK92 Cells in Relapsed and/or Refractory Acute Myeloid Leukemias

Brief Summary: The purpose of this clinical trial is to study genetically engineered NK92 cell therapy in treating patients with CD33 positive acute myeloid leukemias that is relapsed (after stem cell transplantation or intensive chemotherapy) or refractory to further chemotherapy.

Detailed Summary:

PRIMARY OBJECTIVES:

Determine the safety and feasibility of the chimeric antigen receptor NK92 cells transduced with the anti-CD33 vector (referred to as anti-CD33 CAR-NK cells).

SECONDARY OBJECTIVES:

I. For patients with detectable disease, measure anti-leukemia response due to anti-CD33 CAR-NK cell infusions.

II. For patients with stored or accessible leukemia blasts, determine leukemia cell killing by anti-CD33 CAR-NK in vitro.

III. Determine if cellular or humoral host immunity develops against the murine anti-CD33.

OUTLINE: Patients are assigned to 1 group according to order of enrollment.

Patients receive anti-CD33 CAR-NK (coupled with CD28, CD137 and CD3 zeta signalling domains) vector-transduced NK92 cell line on days 0,3, and 5 in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed intensively for 6 months, every 3 months for 2 years, and annually thereafter for 10 years.


Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Current Primary Outcome: Adverse events attributed to the administration of the anti-CD33 CAR-NK cells [ Time Frame: One year ]

Defined as >= Grade 3 signs/symptoms, laboratory toxicities, and clinical events that are possibly, likely, or definitely related to study treatment


Original Primary Outcome: Same as current

Current Secondary Outcome: Objective Response Rate [ Time Frame: Up to one year ]

Anti-leukemia responses to anti-CD33 CAR-NK cell infusions


Original Secondary Outcome: Same as current

Information By: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Dates:
Date Received: October 23, 2016
Date Started: October 2016
Date Completion: September 2018
Last Updated: December 4, 2016
Last Verified: October 2016